Loading, please wait...
Date: Jul 27, 2019 10:00 AM - 03:00 PM
Location: UIW Feik School of Pharmacy, 703 E. Hildebrand, San Antonio, TX, 78212
Fee
$30.00
CE Hours
4.00
CE Units
0.400
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
The University of the Incarnate Word Feik School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
- The participant will only receive credit for programs after receiving a 70% on a post-test and an evaluation form is completed and submitted.
- The entire session must be attended to receive credit. No partial credit will be given.
- Certificates will not be mailed. Contact hours will be uploaded to NABP's CPE Monitor after successful completion of post-test and program evaluation.
- To receive credit, participant profiles must contain a valid NABP e-profile ID number and month/date of birth.
- All requirements to receive credit must be completed within six weeks of participation in the CPE program. Failure to complete requirements within the six-week window will result in no credit awarded to the participant.
|
Please choose a Fee Type from the Drop Down Menu Below:
I am a
|
Upon completion of this activity, participants will be able to:
1. Discuss the process used by the Advisory Committee on Immunization Practices (ACIP) to make changes to
its recommendations.
2. Identify new adult patients eligible for the hepatitis A vaccine following the 2019 adult immunization schedule
update.
3. Screen patients who may be ineligible to receive the live attenuated influenza vaccine due to comorbidities.
4. Describe the difference between ACIP recommendations and FDA indications for human papillomavirus.
its recommendations.
2. Identify new adult patients eligible for the hepatitis A vaccine following the 2019 adult immunization schedule
update.
3. Screen patients who may be ineligible to receive the live attenuated influenza vaccine due to comorbidities.
4. Describe the difference between ACIP recommendations and FDA indications for human papillomavirus.
Speaker(s)/Author(s)
|
Johnathan Cuevas, PharmD
|
Activity Number
0445-0000-19-018-L06-P
Date:
07/27/19
Time:
09:45 AM - 10:45 AM
CE Hours
1.00
Location
FSOP 533 (P3 Classroom)
Upon completion of this activity, participants will be able to:
1. Discuss legislation enacted during the 86th legislative session impacting pharmacy.
2. Identify opportunities for pharmacy as a result of newly-enacted legislation.
3. Describe the importance of pharmacist and technician involvement in the state legislative process.
2. Identify opportunities for pharmacy as a result of newly-enacted legislation.
3. Describe the importance of pharmacist and technician involvement in the state legislative process.
Speaker(s)/Author(s)
|
Debbie Garza |
Activity Number
0445-0000-19-017-L03-P
Date:
07/27/19
Time:
10:45 AM - 11:45 AM
CE Hours
1.00
Upon completion of this activity, participants will be able to:
1. Describe strategies for appropriate opioid use at the patient level, practice
level, state level and national level.
2. Differentiate between the naloxone products on the market and choose
the best product for a given patient.
3. Identify patients at risk and dispense naloxone under current Texas law.
level, state level and national level.
2. Differentiate between the naloxone products on the market and choose
the best product for a given patient.
3. Identify patients at risk and dispense naloxone under current Texas law.
Speaker(s)/Author(s)
|
J. Nile Barnes |
Activity Number
0445-0000-19-020-L01-P
Date:
07/27/19
Time:
12:45 PM - 01:45 PM
CE Hours
1.00
Upon completion of this activity, participants will be able to:
1. Assign a beyond-use-date based on the low, medium and high-risk categories currently in place by USP 797.
2. Assign a beyond-use-date to a sterile compounded product using the newer recommendations to be
published in the updated USP 797 standards.
3. Describe the techniques needed to maintain sterility in the clean room.
4. Discuss and employ solutions for pitfalls in the sterile process when observing or compounding.
2. Assign a beyond-use-date to a sterile compounded product using the newer recommendations to be
published in the updated USP 797 standards.
3. Describe the techniques needed to maintain sterility in the clean room.
4. Discuss and employ solutions for pitfalls in the sterile process when observing or compounding.
Speaker(s)/Author(s)
|
Mike De Luna |
Activity Number
0445-0000-19-019-L07-P
Date:
07/27/19
Time:
01:45 PM - 02:45 PM
CE Hours
1.00